Back to top

A promising advance comes with limits and a need for close monitoring

An injectable medication that researchers call a “functional cure” for adults living with chronic hepatitis B (CHB) has been approved by the U.S. Food and Drug Administration (FDA). Developed by Ionis Pharmaceuticals and licensed to UK-based drugmaker GSK, which collaborated on its clinical development, bepirovirsen (brand name Hibsago), is a first-in-class antisense oligonucleotide for adults who have suppressed hepatitis B virus (HBV) DNA, have been on stable antiviral therapy for at least six months and haven’t developed cirrhosis. 

 

HBV can be transmitted during birth or through bodily fluids, including blood, semen, vaginal fluid and saliva. There are highly effective vaccines for HBV, but it’s estimated that only one-third of the U.S. population has been vaccinated against HCV. When HBV is chronic, it can cause major health problems such as cirrhosis and liver cancer. GSK estimates that chronic hepatitis B affects nearly 2 million people in the U.S. and 240 million worldwide, estimates the World Health Organization (WHO).

 

The standard of care for chronic hepatitis B is lifelong antivirals, a treatment that suppresses—but does not eliminate—the virus. Hibsago is an RNA-based drug that targets the genetic instructions the virus uses to replicate. It also induces an immune response, helping reduce the virus to undetectable levels.

 

Taken alongside hepatitis B oral antiviral medication, Hibsago is injected under the skin.Each 300 mg dose consists of two 150 mg injections. Weeks 1–2, the pair of injections is administered twice weekly, with 3–4 days between doses. Subsequent doses, weeks 3–24, are given once weekly, on the same day each week. The first dose is administered under a healthcare provider’s supervision. After training by the provider, subsequent doses can be self-administered at home.

 

Patients must continue antivirals for at least 24 weeks after their last injection. If they still have an undetectable level of hepatitis in the blood, after 24 weeks, they can stop antivirals indefinitely. Laboratory tests must be measured prior to, during, and following discontinuation of Hibsago.

 

The FDA based its approval on data from a pair of phase 3 studies conducted in the U.S. and in more than 25 other countries in Europe, Asia and the Pacific. B-Well 1 and B-Well 2 enrolled a total of 1,800 adults with chronic hepatitis B who had been exposed to NRTI treatment. Participants received either Hibsago or a placebo. 

 

There’s one big caveat: Hibsago does not work for everyone.

 

Findings published in The New England Journal of Medicine concluded that the combination of Hibsago and antivirals effectively eliminated the virus in one out of five patients (20%), compared with none who received a placebo with antivirals. After having stopped all hepatitis B treatment for 24 weeks, 19% of participants who received Hibsago still had no detectable surface antigen (less than 3,000 IU/mL in their blood) that signals the presence of hepatitis B.

 

The FDA also issued a black box warning for the drug, saying it could lead to liver inflammation and low platelet counts, which could increase the risk of bleeding; it recommended weekly or bi-weekly laboratory monitoring. The most common side effects were injection site reactions, fever, headache and fatigue. 

 

What is a functional cure?

 

Having no detectable surface antigen for six months, with an undetectable viral load, is considered a functional cure for HBV. People in clinical trials who had low surface antigen levels to start with were most likely to see a functional cure with Hibsago. 

 

While a functional cure for 20% of people with chronic hepatitis B may not seem like a lot, it’s a huge improvement over the status quo, according to Chari Cohen, DrPH, MPH, president of the Hepatitis B Foundation. 

 

“Right now, the functional cure rate is about 1% of people with hepatitis B, whether they’re on or off treatment,” she told POSITIVELY AWARE. 

 

Hibsago is a reason to celebrate for several reasons, she added. “This is the first new innovative treatment we’ve had for hepatitis B approved in over 10 years, and even 10 years ago, the drugs that were approved were just versions of the same kind of compound. Hep C had drugs that didn’t cure many people, and then it went up to 10% and 20% and 40%, incrementally, and now they have a cure for 96–97%. So I think we’re going to get there.”

 

Dr. Cohen believes that Hibsago will energize researchers as well as hepatitis B advocates. “If you look at the hepatitis B therapeutics pipeline, it had peaked between 2018 and 2021. In the last 12 months, we’ve seen the pipeline increase, and I think [Hibsago] is going to foster that because it shows what can be done, and it shows that there’s a market for it, and that’s going to bring excitement.”

 

The biggest reason to celebrate, Dr. Cohen said, is that clinicians will have one more tool to fight HBV. “Right now, the choice is treat or not treat, so having another treatment choice is a really good thing.”

 

What about people with HIV and HBV?

 

People living with HIV and HBV have a higher potential for accelerated liver damage and severe health complications compared to having either virus alone. Dr. Cohen believes that approval of Hibsago comes at a good time for people who are dually diagnosed. 

 

“HIV and hepatitis B for a long time were treated with the same kinds of antivirals,” she said.

 

“A tenofovir-based treatment can manage hep B, but now, as you have large segments of the HIV community being moved off of tenofovir-based treatment onto the long-acting antivirals like lenacapavir, what’s going to happen to their hepatitis B? We’re concerned that their hepatitis B may not be controlled and they may wind up with serious liver damage. So [Hibsago] may be a good option for those folks who are pill averse or who can’t handle a daily pill burden.”

 

Who might be prescribed Hibsago?

 

Based on trial data showing better outcomes for people who already had lower surface antigen levels, people who are more likely to achieve a functional cure will be the first to get Hibsago, Dr. Cohen speculated. She added that the introduction of the medication will likely change how clinicians monitor and treat patients with HBV generally, for the better. 

 

“Most clinicians right now are not doing a surface antigen test as part of their patients’ routine monitoring,” she said. “If more people are tested, there will be more data on how many people worldwide have the antigen.” Dr. Cohen noted that the loss of surface antigen is powerful for people living with hepatitis B. “Globally, it’s why people are stigmatized and why people are discriminated against, and so losing that surface antigen will improve quality of life tremendously. It can also decrease fear of liver cancer and decrease fear of transmitting to others throughout their lifespan.” 

 

FDA approval was announced October 20. As of this writing, GSK had not yet released pricing information on Hibsago. 

Prescribing information for Hibsago can be found here. n